Antihypertensive 5,6-diarylpyridazin-3-ones

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Organic Synthesis

Background:

• Hypertension remains a major global health concern, necessitating the development of novel therapeutic agents.
• Existing antihypertensive treatments have limitations, driving research into new chemical entities.
• Pyridazinone derivatives are recognized for their diverse pharmacological activities.

Purpose of the Study:

• To synthesize and characterize a novel series of 5,6-diarylpyridazinones.
• To evaluate the in vivo antihypertensive potential of these synthesized compounds.
• To identify structure-activity relationships for optimized antihypertensive efficacy.

Main Methods:

• Chemical synthesis of 5,6-diarylpyridazinone derivatives.
• In vivo evaluation using the spontaneously hypertensive rat (SHR) model.
• In vivo evaluation using the deoxycorticosterone acetate (DOCA)-induced hypertension model.

Main Results:

• Successful synthesis of a series of 5,6-diarylpyridazinones.
• Demonstration of antihypertensive activity in both SHR and DOCA-induced hypertension models.
• Identification of key structural features correlating with potent antihypertensive effects, including halogen substituents on the 5,6-diphenyl rings, a beta-substituted alkyl group at the 2-position, and an acetyl or cyano substituent at the 4-position.

Conclusions:

• The synthesized 5,6-diarylpyridazinones represent a promising class of compounds for hypertension treatment.
• Specific structural modifications, particularly halogenation and substitution patterns, are crucial for enhancing antihypertensive potency.
• Further investigation into these compounds could lead to the development of new antihypertensive drugs.